MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million

Rhea-AI Summary

MediWound (Nasdaq: MDWD) announced that Vericel (NASDAQ: VCEL), its exclusive North America distributor for NexoBrid, was awarded a 10-year BARDA contract valued at up to $197 million, effective April 1, 2026. The base period is $35 million, including about $10 million over the next 12 months for initial procurement and Vendor Managed Inventory (VMI) setup.

Contract work covers procurement for the U.S. Strategic National Stockpile, VMI establishment, design and validation of a potential U.S. manufacturing facility, development of a room-temperature stable formulation, and clinical development for a possible blast-trauma indication.

Positive

• Contract value up to $197 million over ten years
• Base funding of $35 million includes ~$10 million in next 12 months
• Effective date of contract is April 1, 2026
• Scope includes procurement, VMI, U.S. facility design and formulation development

Negative

• Optional awards mean most of $197M is contingent, not guaranteed
• Realization risk depends on future clinical, manufacturing and procurement milestones

News Market Reaction – MDWD

+3.77%

5 alerts

+3.77% Session close to close

+3.0% Peak in 1 min

$225.30M Market Cap

1.4x Rel. Volume

In the Apr 2 session, MDWD gained 3.77%, reflecting a moderate positive market reaction. Argus tracked a peak move of +3.0% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights a BARDA contract for NexoBrid valued at up to $197 million over 10 year...

Analysis

This announcement highlights a BARDA contract for NexoBrid valued at up to $197 million over 10 years, including a $35 million base period and about $10 million for initial procurement and inventory setup. It extends MediWound’s NexoBrid story beyond burns into potential blast trauma indications and U.S.-based manufacturing. Investors may watch execution on procurement schedules, development of new formulations, and how this contract interacts with the company’s existing multi-year revenue guidance.

Key Figures

BARDA contract value: $197 million Base period value: $35 million Initial procurement: $10 million +5 more

8 metrics

BARDA contract value $197 million Maximum value of ten-year BARDA contract for NexoBrid

Base period value $35 million Base period of BARDA contract, including initial activities

Initial procurement $10 million First 12 months NexoBrid procurement and VMI establishment

Contract duration 10 years Term of BARDA contract effective April 1, 2026

Share price $16.20 Price before/around publication on April 2, 2026

Trading volume 103,455 shares Volume today vs 20-day average of 81,712 shares

52-week high discount 28.02% Price below 52-week high of $22.505

Contract effective date April 1, 2026 Effective date of BARDA contract cited by Vericel

Historical Context

5 past events · Latest: Mar 05 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 05	Annual report filing	Neutral	-2.4%	Form 20-F filing with audited 2025 financials and disclosures.
Mar 05	Earnings results	Positive	-0.8%	Reported 2025 revenue, cash balance, and reaffirmed 2026–2028 guidance.
Feb 19	Earnings date set	Neutral	+0.9%	Announced timing and access details for Q4 and full-year 2025 results.
Feb 17	Conference appearances	Positive	+2.6%	Planned presentations at major healthcare investor conferences.
Jan 12	Corporate update	Positive	-7.9%	Outlined EscharEx trial plans, NexoBrid capacity expansion, and multi-year revenue guidance.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows mixed alignment: the stock sometimes sold off on fundamentally positive updates, but reactions to neutral or administrative items have often aligned with the news tone.

Recent Company History

Over the last few months, MediWound has focused on financial reporting, guidance, and corporate visibility. A January 12 corporate update highlighted EscharEx Phase III progress, a sixfold NexoBrid capacity increase, and 2026–2028 revenue guidance, yet the stock fell 7.86%. Subsequent conference and earnings-date announcements in February saw modest gains. Formal 2025 results and the Form 20-F filing in early March coincided with slight declines. Today’s BARDA-related news ties directly to NexoBrid commercialization, extending that operational narrative.

Key Terms

biomedical advanced research and development authority, vendor managed inventory, strategic national stockpile, blast trauma injuries, +3 more

7 terms

biomedical advanced research and development authority regulatory

"awarded a ten-year contract valued at up to $197 million by the U.S. Biomedical Advanced Research and Development Authority (BARDA)"

A biomedical advanced research and development authority is a government agency that funds and guides the late-stage development and manufacturing of drugs, vaccines, diagnostics and other health technologies, especially those needed for public health emergencies. For investors it matters because its contracts, grants or technical support act like a bridge and safety net—reducing development risk, accelerating timelines and creating a more reliable path to revenue for companies working on critical medical products.

vendor managed inventory technical

"the procurement of NexoBrid, establishment and maintenance of a Vendor Managed Inventory (VMI) system"

Vendor managed inventory is a supply-chain arrangement where the supplier, not the buyer, monitors stock levels and decides when and how much to restock, like a grocery store that automatically refills a household pantry. For investors, it matters because it can lower holding costs, reduce stockouts that hurt sales, and shift inventory risk and cash-flow timing between companies, affecting margins and working capital on financial statements.

strategic national stockpile regulatory

"initial procurement of NexoBrid for the U.S. Strategic National Stockpile and VMI establishment"

A strategic national stockpile is a government-held reserve of critical medical supplies, medicines, vaccines and equipment kept to respond quickly to public health emergencies. For investors, it matters because government purchases, replenishment schedules and stockpile policies can create sudden demand, long-term contracts or regulatory priorities that directly affect makers, distributors and suppliers of those goods—think of it as a national emergency pantry that can drive corporate revenue and risk.

blast trauma injuries medical

"development activities for a potential expanded NexoBrid indication for the treatment of blast trauma injuries"

Blast trauma injuries are the physical harm caused by an explosion’s sudden pressure wave, flying debris, heat and subsequent impacts, producing a mix of wounds to organs, lungs, ears, skin and bones—imagine the combined effect of a powerful shock, shrapnel and a hard fall all at once. Investors should care because these injuries drive hospital demand, long-term care costs, regulatory scrutiny and potential liability for industries tied to explosives, safety equipment, military and energy operations.

room temperature stable formulation technical

"development and procurement of a room temperature stable formulation of NexoBrid"

A room temperature stable formulation is a version of a drug or vaccine designed to keep its potency and safety when stored and shipped at normal ambient temperatures, without refrigeration. For investors this matters because it cuts distribution and storage costs, lowers the risk of product loss, and opens access to markets and care settings where cold storage is limited—acting like a package that can travel easily without a refrigerated truck.

u.s. department of health and human services regulatory

"within the U.S. Department of Health and Human Services (HHS)"

The U.S. Department of Health and Human Services is the federal agency that oversees public health, medical programs, and health-related regulation—think of it as the government’s health manager and referee. Its policies, funding decisions, and regulatory actions (through agencies like the Food and Drug Administration and Centers for Disease Control and Prevention) can change how quickly drugs reach the market, how healthcare providers are paid, and how companies respond during health emergencies, making it a major influence on healthcare and biotech investments.

administration for strategic preparedness and response regulatory

"part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department"

A federal office that coordinates planning, stockpiles, procurement and response for national public-health emergencies like pandemics, biological threats and large-scale medical disasters. Think of it as the country’s emergency manager for medical supplies, vaccines and treatment capacity; its decisions on funding, contracts, product approvals and distribution can directly affect healthcare companies, supply chains and investor expectations about demand and regulatory timing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MediWound Reports BARDA Contract Award to Vericel for NexoBrid^® Valued at up to $197 Million

YAVNE, Israel, April 2, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair, today announced that Vericel Corporation (NASDAQ:VCEL), its exclusive distributor of NexoBrid^® in North America, has been awarded a ten-year contract valued at up to $197 million by the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).

Vericel reported that the contract is for the procurement of NexoBrid, establishment and maintenance of a Vendor Managed Inventory (VMI) system, design and validation of a U.S.-based manufacturing facility, and the development of a next generation formulation and additional indication for NexoBrid.

Vericel further reported that the base period contract of $35 million includes approximately $10 million over the next 12 months for the initial procurement of NexoBrid for the U.S. Strategic National Stockpile and VMI establishment, funding for VMI-related services and initial development activities for a potential expanded NexoBrid indication for the treatment of blast trauma injuries.

According to Vericel, the ten-year contract, effective as of April 1, 2026, also includes optional awards for additional NexoBrid procurement to expand the Strategic National Stockpile, further clinical development for a potential blast trauma indication, design and validation of a potential U.S.-based manufacturing facility and the development and procurement of a room temperature stable formulation of NexoBrid.

About NexoBrid^®

NexoBrid is a topically administered, biological orphan drug for the enzymatic removal of eschar in patients with deep partial- and full-thickness thermal burns. It selectively removes non-viable tissue while preserving viable tissue and is approved for use in adults and pediatric patients in over 40 countries, including the United States, European Union, and Japan.

NexoBrid development has been supported with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), under contract HHSO100201500035C.About MediWound Ltd.

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company pioneering enzymatic, non-surgical therapies for tissue repair. The company’s FDA-approved biologic, NexoBrid^®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the United States, European Union, Japan, and additional international markets. MediWound’s late-stage pipeline product, EscharEx^®, is an investigational therapy for the debridement of chronic wounds, with potential to become a new standard of care in wound management.

For more information, visit www.mediwound.com and follow us on LinkedIn and X (formerly Twitter).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause MediWound’s actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are based on current expectations, estimates, forecasts and projections about future events and are subject to a number of risks and uncertainties, many of which are beyond our control.
This press release is based, in part, on information reported by Vericel Corporation, MediWound’s exclusive distributor of NexoBrid® in North America, regarding its contract with BARDA, and MediWound has not independently verified such information.
Forward-looking statements can be identified by words such as “anticipates,” “intends,” “plans,” “expects,” “believes,” “estimates,” “potential,” “will,” “would,” “should,” “could,” “may,” and similar expressions. In particular, this press release contains forward-looking statements regarding the expected benefits related to the BARDA contract awarded to Vericel, including potential procurement of NexoBrid^®, development activities, and the potential impact on MediWound.
Factors that could cause actual results to differ materially include, but are not limited to: uncertainties related to the timing, scope and extent of BARDA procurement and the exercise of contract options; MediWound’s relationship with Vericel and its role under the distribution agreement; risks related to regulatory approvals and clinical development activities; the inherent uncertainties associated with the development and commercialization of biopharmaceutical products; market acceptance of our products; competition; our ability to manufacture and supply our products; and other factors described in MediWound’s filings with the U.S. Securities and Exchange Commission (“SEC”), including in our Annual Report on Form 20-F for the year ended December 31, 2025, filed on March 5, 2026, and subsequent reports on Form 6-K.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. MediWound undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

MediWound Contacts:
Hani Luxenburg         Chief Financial Officer MediWound Ltd. ir@mediwound.com		Daniel Ferry Managing Director LifeSci Advisors, LLC daniel@lifesciadvisors.com

FAQ

What did MediWound (MDWD) announce about the BARDA contract for NexoBrid on April 2, 2026?

MediWound said Vericel won a 10-year BARDA contract up to $197 million, effective April 1, 2026. According to Vericel, the award covers procurement, VMI, U.S. manufacturing design, formulation development and potential blast-trauma clinical work.

How much funding is guaranteed in the BARDA contract for NexoBrid and what is near-term funding for MDWD (MDWD)?

The guaranteed base period is $35 million, including about $10 million over the next 12 months. According to Vericel, that near-term funding covers initial procurement, VMI establishment and initial development activities.

What activities does the BARDA contract require for NexoBrid that could affect MediWound (MDWD)?

The contract requires procurement for the national stockpile, establishing a Vendor Managed Inventory (VMI), designing a U.S. facility and developing a room-temperature formulation. According to Vericel, it also funds potential blast-trauma clinical development.

When does the BARDA contract for NexoBrid become effective and how long is its term for MediWound (MDWD)?

The contract is effective as of April 1, 2026 and runs for ten years with optional awards. According to Vericel, the ten-year structure includes a base period and additional optional procurement and development awards.

What does the BARDA award mean for MediWound (MDWD) revenue certainty?

It provides some near-term certainty via a $35 million base, but most of the $197 million is optional. According to Vericel, additional value depends on exercised options for procurement, clinical work and facility validation.